Navigation Links
RegeneRx Receives Israeli Patent for Treating and Repairing Heart Damage
Date:2/25/2015

ROCKVILLE, Md., Feb. 25, 2015 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx") today announced that it has received an Israeli patent with claims for preventing, inhibiting or reducing heart tissue deterioration, injury or damage, and for restoring heart tissue.  The patent includes claims using thymosin beta 4, various fragments and analogues.  The patent will expire in July 2026.

About RegeneRx Biopharmaceuticals, Inc. (www.regenerx.com)

RegeneRx is focused on the development of a novel therapeutic peptide, Thymosin beta 4, for tissue and organ protection, repair and regeneration. RegeneRx currently has three drug candidates in clinical development for ophthalmic, cardiac and dermal indications, three active strategic licensing agreements in China, Pan Asia (Korea, Japan, and Australia, among others) and the U.S., and has an extensive worldwide patent portfolio covering its products. RGN-259, the Company's ophthalmic drug candidate, has been designated an orphan drug for the treatment of neurotrophic keratopathy (NK), which is a primary focus of RegeneRx's clinical development efforts in the U.S.  RegeneRx was recently allowed by the FDA to move into Phase III clinical trials with RGN-259 for the treatment of patients with NK. The Company's partners are in various stages of development of RGN-259 for dry eye syndrome in their respective territories.

Forward-Looking Statements

Any statements in this press release that are not historical facts are forward-looking statements made under the provisions of the Private Securities Litigation Reform Act of 1995. Any forward-looking statements involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements.  There can be no assurance that any issued patents or licenses held by the Company or patent applications filed by the Company in the U.S. or any other country will result in future value.  Please view these and other risks described in the Company's filings with the Securities and Exchange Commission ("SEC"), including those identified in the "Risk Factors" section of the annual report on Form 10-K for the year ended December 31, 2013, and subsequent quarterly reports filed on Form 10-Q, as well as other filings it makes with the SEC. Any forward-looking statements in this press release represent the Company's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. The Company specifically disclaims any obligation to update this information, as a result of future events or otherwise, except as required by applicable law.


'/>"/>
SOURCE RegeneRx Biopharmaceuticals, Inc.
Copyright©2015 PR Newswire.
All rights reserved

Related medicine technology :

1. RegeneRx Releases Letter to Shareholders
2. AtheroNova Receives Additional Notices of Debt Acceleration
3. Lumicera Receives URAC Specialty Pharmacy Accreditation
4. AtheroNova Receives Notice of Issuance of Its 3rd US Patent
5. Vermillion Receives ISO 13485 Certification for Companys Quality Management System
6. NanoSmart Receives FDA Orphan Drug Designation for ANA-Conjugated Liposomal Doxorubicin for the Treatment of Ewings Sarcoma
7. Pressure BioSciences Receives First Purchase Order for its Barozyme HT48 High-throughput System
8. Advanced Prenatal Therapeutics Receives Notice of Allowance for Preeclampsia Device
9. CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program
10. AliveCor Receives CE Mark on Atrial Fibrillation Algorithm
11. NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/8/2019)... MS (PRWEB) , ... October 08, 2019 , ... ... recently participated in an advanced dental implant seminar to enhance his skill and ... the country, The Implant Dentistry Continuum™ is a four-part series of classes that ...
(Date:10/8/2019)... , ... October 08, 2019 , ... For many Americans, ... cost for procedures is paid out of pocket. Yearly insurance payouts are generally capped ... dental insurance, including 46 million people who are 65 or older. (Standard Medicare does ...
(Date:10/8/2019)... ... ... Villa Healthcare, a leader in skilled nursing, celebrated their outstanding and caring employees ... their work means to them. The essays poured in and inspired tears, laughter ... Anticipation was high as finalists gathered in Skokie on a perfectly fall afternoon ...
Breaking Medicine Technology:
(Date:10/10/2019)... ... October 10, 2019 , ... Santa ... (IT) services for the healthcare industry, has completed the first phase of a ... the Commonwealth of The Bahamas towards a fully integrated health information management system ...
(Date:10/8/2019)... ... October 08, 2019 , ... SoCal Adolescent Wellness announces the opening of ... expansion of our services to better serve the families in Orange County," said Becca ... to see the extraordinary impact this pre-intervention program has on the lives of the ...
(Date:10/8/2019)... ... October 08, 2019 , ... ... in live samples, Meiqing Shi, associate professor with the University of Maryland Department ... latest paper published in Nature Communications, Shi and his lab have discovered a ...
(Date:10/8/2019)... ... ... Smile Brands Inc. has been named one of the happiest companies in ... dental support organization with nearly 440 affiliated practices across 18 states, has a deeply ... Award is the latest in a series of accolades the company has ...
(Date:10/8/2019)... ... October 08, 2019 , ... Fewer than 50 percent of ... reproducible. Rigor in bioanalytical method validation is emerging in the form of a ... of the time) and senior scientists add the management of an offshore team ...
Breaking Medicine News(10 mins):